Latest clinicial results with Bonolive® published in peer reviewed journal
Press release
Our latest clinical study confirms the beneficial effects of Bonolive® on Menopause Symtoms and women’s overall quality of life.
Solabia Nutrition announces the release of our latest peer-reviewed clinical study. It is published in the international journal “Nutrients”. The manuscript is authored by scientists of the departments of Human Biology and Nutrition and Movement Sciences at Maastricht University, the Netherlands and scientists of Solabia Nutrition.
This randomized double-blind placebo controlled trial aimed to investigate the effect of Bonolive® on Menopausal Symptoms including physical and psychological domains.
Bonolive®: award-winning olive leaf extract for women’s health
Bonolive® is a clinically validated extract from Manzanilla olive leaves, standardized for 40% oleuropein. In previous published clinical studies in menopausal women, Bonolive® has established its beneficial effects on increasing osteocalcin levels, reducing joint pain and improving blood lipid profile – all key domains for Menopausal women’s quality of life! Moreover, Bonolive® won the award for Innovation in Women’s Health 2024!
The FEMMED study:
Olive Leaf Extract Supplementation Improves Postmenopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Parallel Study on Postmenopausal Women
Introduction
Menopause marks the end of a woman’s reproductive years, caused by a decline in ovarian hormone production like estrogen. This gradual process affects various organs like skeletal muscle and skin. Menopause also comes with various physical and psychological symptoms that impact health and quality of life. For example: hot flashes, sleep issues, fatigue, skin dryness and reduced sexual desire. Hormone replacement therapy (HRT) is a popular treatment option, though it has side effects. Therefore, women are looking for a natural and hormone-free solution for menopause symptoms.
Methods
For this RCT, 60 postmenopausal women aged between 47-70 years completed the trial. They took 250mg Bonolive® or placebo daily for 12 weeks and completed measurements at baseline, 6 weeks and 12 weeks. Measurements included DEXA scan, validated Menopause Quality of Life questionnaire (MENQoL), blood samples and more. The full study design can be seen in the publication: https://www.mdpi.com/2072-6643/16/22/3879
Results
The overall MENQoL score was significantly improved (p=0.027) after 6 weeks Bonolive® intake compared to placebo. This score included Vasomotor, Psychological, Physical and Sexual domains.
This study also confirms Bonolive®’s treatment effect on lowering triglycerides levels (p=0.010) and improving TG/HDL ratio (p=0.029).
Moreover, a significant increase in bone mineral density (p=0.019) of the dominant arm was observed after taking Bonolive® compared to placebo.
Access all previously published studies with Bonolive® here
Conclusion
The FEMMED study demonstrated the potential of Bonolive® as a 100% natural and safe solution for Menopause care. This is indicated by the significant improvement in menopause symptoms as analyzed via the internationally validated MENQoL Score.
Bonolive® offers consumers a science-based and plant-based solution to address the challenges of Menopause.
Access more preliminary data with Bonolive® and skin health
About Solabia Nutrition
Solabia Nutrition, based in Maastricht, the Netherlands, develops and supplies proprietary bioactive formulations to the health and sports nutrition industry. All Solabia Nutrition’s products are clinically tested and from natural origin. The main focus areas are gut microbiome, brain health, energy & vitality and skin health.
Feel free to contact via contact@solabia.com for more information on the possibilities our ingredients have to offer.
